# Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC

> **NCT06153368** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Cadonilimab+mFOLFIRINOX

## Key facts

- **NCT ID:** NCT06153368
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-19
- **Primary completion:** 2024-11-27
- **Final completion:** 2025-11-27
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06153368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06153368, "Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06153368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*